Precision Oncology
Guiding Oncology Therapies from Early Detection of Response to Approval
Partner with a collaborative oncology CRO that believes in your drug discovery as much as you do.
OUR CAPABILITIES
We Have You Covered Throughout Every Phase
Clinical Study Management
We offer Phase I, II and III clinical trial design, planning and execution utilizing a data-driven, flexible and efficient approach. Using innovative and precise methods for capturing and analyzing data, we identify early signals of response to put your oncology therapy on the path to approval.
Preclinical
In the early phase of oncology research, TD2 sets you up for success with an extensive suite of preclinical tools, over 400 models of cancer as well as extensive knowledge in designing and adapting your study to maximize data value and predict patient response.
Regulatory Support
Your therapy’s journey to approval requires a veteran team dedicated to navigating each phase of development. At TD2, we manage the most complex aspects of the regulatory process including IND readiness assessment, program evaluation, IND development and filings, and all FDA interactions.
PK/ADME
Drug metabolism and pharmacokinetic(DMPK) analyses are key to successful drug development and approval, and TD2 can help determine which tests are the best fit early through a diverse set of assays to support your program.
WHAT WE DO
The Precision Oncology CRO
We are your scientifically-driven and flexible partner for drug development. Our team is fully dedicated to oncology – it is all we do – combining innovation and expertise to quickly move your therapies from preclinical development into clinical trials. Adaptive and forward-thinking – we guide your therapy through the most critical development milestones from the lab to planning your regulatory and clinical strategy and ultimately approved.
ABOUT TD2
Accelerating Cancer Drug Development
Since 2003, TD2 has made an impact beyond what is expected of a traditional oncology CRO. Not only do we work with hundreds of biotech and pharma companies to rapidly move new therapy discoveries to market through proactive problem solving and strategic collaboration, but we are also drug development innovators. The breadth of our services gives us the unique ability to translate scientific hypotheses generated in a lab setting into patient responses in the clinic. Our results consistently outpace our competition due to a dynamic, flexible and highly specialized team that is laser-focused on oncology.
